- •
Positron emission mammography shows sensitivity similar to MR imaging in detecting malignant breast lesions with better specificity than MR imaging.
- •
Breast PET can be used in women in whom breast MR imaging is contraindicated.
- •
Breast imagers should interpret breast PET to assure full correlation with prior breast imaging, history, and appropriate management in conjunction with a multidisciplinary specialty team.
Use of Breast-Specific PET Scanners and Comparison with MR Imaging
Section snippets
Key points
Breast-specific PET devices
Whole-body PET (WBPET) and PET-CT are not optimal for evaluation of the breasts due to supine positioning and low resolution (5–6 mm), which limit detection of subcentimeter cancers.3 Breast PET uses detectors positioned close to the breasts either similar to mammography with gentle stabilization or in the prone or semiprone position. PET requires coincidence detection of the pair of 511 KeV gamma rays emitted in opposite directions at the time of annihilation of the positron. This requirement
Imaging protocol and radiation exposure
In clinical studies using breast-specific PET systems, patients are injected with approximately 185 to 370 MBq (5–10 mCi) FDG after fasting for 4 to 6 hours. Blood glucose is tested prior to injection and should be in the normal range. Patients must rest quietly for 60 to 90 minutes following injection prior to commencing imaging. For PEM systems, typically both craniocaudal and mediolateral oblique views are obtained for 5 to 10 minutes of scan time per breast per view. For other systems, the
Local extent of disease
There is a lack of consensus about the use of preoperative MR imaging to assess local extent and select patients for breast-conserving treatment.13 A large prospective multicenter trial of PEM and MR imaging in 388 women with newly diagnosed biopsy-proven cancer, where breast-conserving therapy was planned, was led and reported by Berg and colleagues.1 Of 388 index breasts with cancer, 75 (19%) ultimately were pure ductal carcinoma in situ (DCIS). For the 386 index malignancies that had
Axilla
Often it is difficult to include the axillae with breast-specific PET because of positioning similar to mammography or even on a prone table. In the prospective multicenter trial described,1 the false-positive and false-negative rates for axillary nodal metastases were high for both PEM and MR imaging. Of 19 axillae suspicious on PEM, only 10 (53%) actually had nodal metastatic disease; of 27 axillae suspicious on MR imaging, only 13 (48%) had metastatic nodes. Of 326 axillae negative on PEM,
Quantification
Using WBPET, quantitative, and for PEM, semiquantitative uptake of FDG have been shown to correlate with known histopathologic and immunohistochemical prognostic factors including risk of nodal metastases; greater uptake predicts response to chemotherapy.25, 26 Increasing uptake has been shown with increasing tumor grade and with triple receptor-negative tumor type.15, 25 Lower uptake has been observed in invasive lobular carcinoma.15 Like the standardized uptake value (SUV) used in whole-body
Background 18F-2-deoxy-2-fluoro-d-glucose uptake and breast density
Uptake of FDG in normal breast tissue increases with visual mammographic BI-RADS breast density and decreases with patient age/postmenopausal status. An early retrospective study of 94 women with suspicious breast lesions29 looking at a region of interest in the normal contralateral breast showed average mean (and maximum) background glandular PUV of 0.33(0.60) in fatty breasts, 0.41(0.72) in breasts with scattered fibroglandular density, 0.65(1.05) in heterogeneously dense breasts, and
Response to primary chemotherapy
Noritake and colleagues32 compared the performance of PEM with that of WBPET in assessing the therapeutic response to neoadjuvant chemotherapy in 20 patients. Patients were imaged at 3 time points: before, during (interim), and after neoadjuvant chemotherapy. PEM PUVmax was highly correlated with SUVmax on WBPET (Pearson correlation coefficient r = 0.78). At the interim time point, when therapy could be changed based on imaging findings, reduction in PUVmax did not distinguish patients who
Other applications
Although 1 study of 265 women, including 165 who were asymptomatic, used PEM to screen for breast cancer,33 this will not be discussed further due to the substantial whole-body radiation exposure and patient preparation that render breast PET impractical for screening. In 1 study34 evaluating PEM in women with suspicious calcifications going to biopsy, among 40 patients with 15 malignancies, PEM identified 14 (93.3%) cancers with 1 false-negative intermediate-grade DCIS and 1 false-positive
Summary
Breast-specific PET imaging demonstrates high sensitivity for breast cancer and has shown promise for evaluating extent of disease in patients diagnosed with breast cancer. Although PEM and MR imaging are complementary, and the use of both improves overall performance, it is not recommended to use both because of the substantial cost and minimal added benefit in such an approach. Breast MR imaging is widely used in breast imaging clinics. Although the lack of specificity is a known disadvantage
References (40)
- et al.
MRI for breast cancer screening, diagnosis, and treatment
Lancet
(2011) - et al.
Imaging sensitivity of dedicated positron emission mammography in relation to tumor size
Breast
(2012) - et al.
The value of positron emission mammography (PEM) in management of breast cancer
Pract Radiat Oncol
(2013) - et al.
Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis
Neoplasia
(2001) - et al.
MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis
Clin Radiol
(2017) - et al.
Background (1)(8)F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI
Eur J Radiol
(2013) - et al.
Curies, and grays, and sieverts, oh my: a guide for discussing radiation dose and risk of molecular breast imaging
J Am Coll Radiol
(2015) - et al.
Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast
Radiology
(2011) - et al.
Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging
Eur J Nucl Med Mol Imaging
(2011) - et al.
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations
J Clin Oncol
(2000)
PET-guided breast biopsy
Breast J
Current status of dedicated breast PET imaging
Curr Radiol Rep
Dedicated PET scanners for breast imaging
Phys Med Biol
Interpretation of positron emission mammography: feature analysis and rates of malignancy
AJR Am J Roentgenol
ACR BI-RADS Magnetic Resonance Imaging
Interpretation of positron emission mammography and MRI by experienced breast imaging radiologists: performance and observer reproducibility
AJR Am J Roentgenol
Positron emission mammography image interpretation for reduced image count levels
J Nucl Med
Radiation doses and cancer risks from breast imaging studies
Radiology
Whole-body PET/CT scanning: estimation of radiation dose and cancer risk
Radiology
Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT
Eur J Nucl Med Mol Imaging
Cited by (15)
Breast imaging: Beyond the detection
2022, European Journal of RadiologyCitation Excerpt :Indications for PEM include: diagnosis and staging of breast cancer, detection of contralateral breast cancer and detection of recurrences. PEM has also demonstrated increasing potential importance in the evaluation of response to chemotherapy and in presurgical planning [47]. Nowadays, the hybrid technology of simultaneous or integrated PET/MRI scanners offers the advantages of combining the high sensitivity of MRI and the high specificity of FDG-PET within a single examination.
Attenuation correction and truncation completion for breast PET/MR imaging using deep learning
2024, Physics in Medicine and BiologyThe current role of nuclear medicine in breast cancer
2023, British Journal of RadiologyA Correlative Approach to Breast Imaging
2023, Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative ApproachRole of PET-CT in the staging of locally advanced breast cancer
2022, Revisiones en Cancer
Disclosures: The authors have nothing to disclose.